Ovarian Cancer Clinical Trial
Official title:
A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. It is not yet known whether receiving paclitaxel and
carboplatin with epirubicin is more effective than paclitaxel and carboplatin alone for
ovarian epithelial, fallopian tube, or peritoneal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and
carboplatin with or without epirubicin in treating patients who have stage IIB, stage III,
or stage IV invasive ovarian epithelial, fallopian tube, or peritoneal cancer.
OBJECTIVES:
- Compare progression free survival and overall survival in patients with stage IIB, III,
or IV invasive ovarian epithelial, fallopian tube, or peritoneal cancer treated with
paclitaxel and carboplatin with or without epirubicin.
- Compare the toxicity of these 2 regimens in these patients.
- Compare the quality of life of patients treated with these 2 regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by center and type
of surgery (delayed surgery: 3 courses of chemotherapy before surgery vs primary surgery:
optimally debulked stage IIB or III [residual tumor less than 1 cm] vs primary surgery:
suboptimally debulked stage IV [residual tumor 1 cm or greater]).
Surgery
- Patients are assigned to one of two surgery groups:
- Group A: Patients undergo primary surgery comprised of hysterectomy, bilateral
salpingo-oophorectomy (BSO), omentectomy, and resection of all tumor masses, if
possible, before beginning chemotherapy. Patients with residual disease greater than 1
cm after completion of primary surgery receive 3 courses of chemotherapy, followed
within 6 weeks by interval debulking surgery, followed within 3 weeks by the fourth
course of chemotherapy.
- Group B: Patients undergo delayed surgery comprised of hysterectomy, BSO, omentectomy,
and resection of all tumor masses, if possible, after completion of 3 courses of
chemotherapy.
Chemotherapy
- Patients are randomized to 1 of 2 chemotherapy arms:
- Arm I: Patients receive epirubicin IV over 15-20 minutes, paclitaxel IV over 3 hours,
and carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses.
Patients with residual tumor after completion of 6 courses may receive 3 additional
courses.
- Arm II: Patients receive paclitaxel and carboplatin as above but no epirubicin. Quality
of life is assessed before beginning study, after completion of courses 3, 6, and 9 (if
applicable), and then at 6 and 12 months after completion of study treatment.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.
PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |